Last $39.95 USD
Change Today -0.59 / -1.46%
Volume 665.6K
WX On Other Exchanges
New York
As of 4:15 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

wuxi pharmatech cayman-adr (WX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/13/15 - $42.31
52 Week Low
05/15/14 - $29.84
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

wuxi pharmatech cayman-adr (WX) Related Businessweek News

No Related Businessweek News Found

wuxi pharmatech cayman-adr (WX) Details

WuXi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products. The Manufacturing Services segment produces and manufactures advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and for commercial products, as well as produces biologics. The company sells its products directly to pharmaceutical, biotechnology, and medical device companies. It has strategic collaboration agreement with Foundation Medicine, Inc. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is based in Shanghai, China.

7,445 Employees
Last Reported Date: 04/15/14
Founded in 2000

wuxi pharmatech cayman-adr (WX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

wuxi pharmatech cayman-adr (WX) Key Developments

WuXi PharmaTech (Cayman) Inc. Enters into Syndicated Loan Agreement

WuXi PharmaTech (Cayman) Inc. announced that it has entered into a syndicated loan facility to borrow up to $165 million from a consortium of banks in Asia led by Citibank. The borrowing will incur interest at a rate of LIBOR plus 2.89%, including all expenses, and will be repaid in four installments over 18-36 months.

WuXiPRA Announces Executive Changes

WuXiPRA announced appointments of two key executives. Liedong Xu was named Executive Vice President and Chief Operations Officer. He brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono. Jason Wu was appointed Executive Vice President and Chief Medical Officer of WuXiPRA. In 2012, WuXi PharmaTech and PRA formed the joint venture WuXiPRA to provide comprehensive Phase I-IV clinical trial services in mainland China, Hong Kong and the Asia region.

WuXi PharmaTech Provides Update of 2014 Financial Guidance

WuXi PharmaTech updated earnings guidance for the year 2014. For the year, the company expects to achieve total revenues of approximately $674 million, compared to previous guidance of $670 million to 672 million. The company expects to achieve diluted EPS of approximately $1.87 (non-GAAP) and approximately $1.56 (GAAP), compared to previous guidance of 1.83 to 1.86 (non-GAAP) and $1.55 to 1.58 (GAAP). These preliminary 2014 results are unaudited and remain subject to the finalization of the company's year-end closing, reporting, and audit processes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WX:US $39.95 USD -0.59

WX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $76.67 USD -0.10
Ergomed PLC 166.00 GBp +1.00
Hangzhou Tigermed Consulting Co Ltd CNY43.71 CNY +0.67
ICON PLC $69.01 USD -0.43
PAREXEL International Corp $64.46 USD -0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation WX Industry Range
Price/Earnings 26.3x
Price/Sales 4.4x
Price/Book 3.8x
Price/Cash Flow 25.3x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WUXI PHARMATECH CAYMAN-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at